Summit Ascent Holdings, a Hong Kong-listed company led by billionaire Lawrence Ho, has obtained majority control in of a casino project in the eastern Russian city of Vladivostok.
Summit Ascent will pay $20.2 million for an additional 14% stake in the project held by Oleg Drozdov, a businessman who has been detained in a probe unrelated to the casino. ��he unexpected detention of Mr. Drozdov has created unforeseen financing constraints��for the project, according to a Summit Ascent announcement yesterday.
The purchase will increase Summit�� stake to 60%. Melco International, Ho�� main Hong Kong-listed holding company, also owns 5%. Taiwan-listed Firich Enterprises, a supplier of electronics equipment, owns 20%. Drozdov�� Elegant City still has 15% of the Russian casino resort.
Vladivostok is located north of China�� Heilongjiang Province, and the investment is expected to give Summit Ascent a early-mover advantage in an eastern Russian market that has held promise since the country eased rules on casino investments in 2009.
Hot Cheap Companies To Watch In Right Now: Immunomedics Inc.(IMMU)
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. The company?s products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study completed product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib/II clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. Its early phase clinical trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug conjugate therapy. The com pany also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers. In addition, it markets and sells a diagnostic product, LeukoScan, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. Immunomedics, Inc. has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd., to develop vaccines against cancers that include melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Advisors' Opinion:- [By Sean Williams]
In terms of clinical data, small-cap biotechnology company Immunomedics (NASDAQ: IMMU ) jumped by double digits after reporting early stage, but nonetheless positive, data from its antibody-drug conjugate program. Two of Immunomedics' ADC's, IMMU-130 which is targeted at metastatic colorectal cancer, and IMMU-132, which is being tested on 13 different cancer types, demonstrated tumor shrinkage and some partial responses. We're still a long way from an approval, but ADC's certainly look like one pathway to effectively treating cancer. Make sure this is a company you've added to your Watchlist.
- [By Roberto Pedone]
Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Immunomedics (IMMU), which is focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. This stock is off to a very bullish start in 2013, with shares up sharply by 110%.
If you take a look at the chart for Immunomedics, you'll notice that this stock has been uptrending decent for the last month, with shares moving higher from its low of $4.85 to its recent high of $6.54 a share. During that uptrend, shares of IMMU have been consistently making higher lows and higher highs, which is bullish technical price action. This uptrend is coming after shares of IMMU downtrended during July from $6.91 to that $4.65 a share low. Shares of IMMU are now starting to push within range of triggering a big breakout trade.
Market players should now look for long-biased trades in IMMU if it manages to break out above some near-term overhead resistance at $6.54 a share and then once it clears its 52-week high at $6.91 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.15 million shares. If that breakout triggers soon, then IMMU will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $8 to $10 a share, or possibly even north of $10 a share.
Traders can look to buy IMMU off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $5.52 a share or below more support at $5 a share. One can also buy IMMU off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Sean Williams]
What: Shares of Immunomedics (NASDAQ: IMMU ) , a biopharmaceutical company researching monoclonal, antibody-based products to treat cancer and other autoimmune disorders, jumped as much as 15% after providing a clinical update on its antibody-drug conjugate programs.
- [By Wallace Witkowski]
Immunomedics Inc. (IMMU) �shares rose 19% to $6.18 on heavy volume after the small cap biotech said it just started treating patients with its pancreatic cancer drug in a late-stage clinical trial.
Top Gas Utility Stocks To Watch Right Now: Ever-Glory International Group Inc.(EVK)
Ever-Glory International Group, Inc., together with its subsidiaries, engages in the manufacture, distribution, and sale of apparel for women, men, and children. Its products include coats, jackets, slacks, skirts, shirts, trousers, vests, skiwear, down jackets, knitwear, and jeans. The company offers its products to the casual wear, sportswear, and outerwear brands, as well as retailers, such as department stores, flagship stores, stores-within-a-store, and specialty stores primarily in Europe, the United States, Japan, and the People?s Republic of China. As of December 31, 2010, it operated 293 retail stores in the People?s Republic of China. The company is based in West Covina, California.
Advisors' Opinion:- [By John Udovich]
Small cap apparel stock G-III Apparel Group, Ltd (NASDAQ: GIII) has been making bullish moves lately plus the stock is up 97.1% since the start of the year, making it the third best performing apparel stock (according to stock screener Finviz)�after small cap�Ever-Glory International Group Inc (NYSEMKT: EVK) and mid cap Fifth & Pacific Companies Inc (NYSE: FNP) followed by mid cap Hanesbrands Inc (NYSE: HBI). But is the G-III Apparel Group dressed for long term success for investors?
Top Gas Utility Stocks To Watch Right Now: Capex SA (CAPX)
Capex SA is an Argentina-based company primarily engaged in the energy sector. The Company�� main activities include the generation and sale of electric energy; the exploration and exploitation of oil and gas, and the production, distribution and marketing of propane, butane and gasoline. The Company operates a liquefied petroleum gas (LPG) plant which is located in the province of Neuquen. As of December 31, 2011, the Company owned such subsidiaries as Hychico SA and Servicios Buproneu SA. Advisors' Opinion:- [By Dividends4Life]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description: 1. Avg. High Yield Price 2. 20-Year DCF Price 3. Avg. P/E Price 4. Graham Number CVX is trading at a discount to only 3.) above. The stock is trading at a 44.9% premium to its calculated fair value of $82.00. CVX did not earn any Stars in this section. Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description: 1. Free Cash Flow Payout 2. Debt To Total Capital 3. Key Metrics 4. Dividend Growth Rate 5. Years of Div. Growth 6. Rolling 4-yr Div. > 15% CVX earned two Stars in this section for 2.) and 3.) above. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. CVX earned a Star for having an acceptable score in at least two of the four Key Metrics measured. The company has paid a cash dividend to shareholders every year since 1912 and has increased its dividend payments for 27 consecutive years. Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description: 1. NPV MMA Diff. 2. Years to > MMA The NPV MMA Diff. of the $256 is below the $800 target I look for in a stock that has increased dividends as long as CVX has. The stock's current yield of 3.37% exceeds the 3.31% estimated 20-year average MMA rate. Memberships and Peers: CVX is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: BP plc (BP) with a 4.7% yield, Exxon Mobil
Top Gas Utility Stocks To Watch Right Now: Verifone Systems Inc.(PAY)
Verifone Systems, Inc. designs, markets, and services electronic payment solutions in North America and internationally. It provides system solutions, including countertop electronic payment systems that accepts magnetic, smart card, contactless/ radio frequency identification(RFID) cards, and near field communication(NFC) enabled mobile phones; secure PIN pads that support credit and debit transactions; and wireless system solutions that support Internet protocol-based code division multiple access, general packet radio service, bluetooth, and wireless fidelity technologies. The company also offers products for consumer-activated functionality at the point of sale; contactless/NFC payment solutions consisting of contactless readers primarily for consumer-activated transactions with contactless cards, tokens, and NFC-enabled mobile phones; and Gemstone family of products comprising integrated electronic payment systems for petroleum companies. In addition, it provides serv er-based payment processing software and middleware; unattended and self-service payments hardware and software integration modules, such as vending machines, ATMs, ticketing kiosks, petroleum dispensers, public transportation turnstiles and buses, self-checkout, bill payment, and photo finishing kiosks; retail bank branch solutions; mass transportation solutions; and network access solutions. Further, the company offers client services, customized application development, advertising publishing, taxi payments and advertising, cardholder data security, annual software maintenance program, and repair services. It serves financial institutions, payment processors, petroleum companies, large retailers, taxi fleets, government organizations, healthcare companies, independent sales organizations, and advertisers. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc in May 2010. VeriFone Systems, Inc. is headquartered in San Jose, California.
Advisors' Opinion:- [By Laura Brodbeck]
Tuesday
Earnings Expected From: Jabil Circuit, Inc. (NASDAQ: CSPI), Verifone Systems, Inc. (NYSE: PAY) Economic Releases Expected: Japanese trade balance, New Zealand current account, US current account, US CPIWednesday
- [By Roland Head]
VeriFone (NYSE: PAY ) may fall this morning after the firm revealed a second-quarter loss of $0.54 per share after markets closed last night, down from a $0.03 per-share profit for the same period last year. The firm blamed high legal costs for the loss, but its shares closed down by 5% last night and are down by almost 15% in premarket trading this morning. Vera Bradley may also fall after reporting a 27% fall in first-quarter profit and cutting its full-year guidance; the handbag designer's share price is down 11% in premarket trading this morning.
- [By Evan Niu, CFA]
What: Shares of VeriFone Systems (NYSE: PAY ) have jumped today, up by 13% at the high, after the company announced it scored a lucrative contract.
Top Gas Utility Stocks To Watch Right Now: Spreadtrum Communications Inc.(SPRD)
Spreadtrum Communications, Inc., through its subsidiaries, operates as a fabless semiconductor company that designs, develops, and markets baseband processor and RF transceiver solutions for wireless communications and mobile television markets. It offers a portfolio of integrated baseband processor solutions that support a range of wireless communications standards, including global system for mobile communication (GSM), general packet radio service (GPRS), enhanced data rates for GSM evolution (EDGE), time division synchronous code division multiple access (TD-SCDMA), and high speed packet access (HSPA), as well as offer an array of multimedia capabilities, such as MP3 digital audio playback, touch screen, JAVA acceleration, digital camera support, motion JPEG, MPEG4, AVS and H.264 digital video playback, and 64-channel polyphonic ringtone playback. The company also provides single-chip CMOS multi-mode RF transceivers that perform across various standards covering GSM/GP RS, EDGE, wideband code division multiple access, TD-SCDMA, and high speed uplink/downlink packet access. In addition, it designs, develops, and markets a CMMB-based channel demodulator and audio/video decoder processor solution for the mobile television market. The company sells its products directly, as well as through distributors to brand manufacturers, independent design houses, and original design manufacturers primarily in China, Hong Kong, and Macau. Spreadtrum Communications, Inc. was founded in 2001 and is headquartered in Shanghai, the People?s Republic of China.
Advisors' Opinion:- [By Dan Radovsky]
Chinese semiconductor maker Spreadtrum (NASDAQ: SPRD ) has received a buyout offer valued at up to $1.5 billion from Tsinghua Unigroup, a subsidiary of Chinese government-owned Tsinghua Holdings, Spreadtrum announced today.
- [By Bloomberg News]
The Bloomberg China-US 55 Index (CH55BN), the measure of the most- traded U.S.-listed Chinese companies, added 0.2 percent in New York yesterday. Spreadtrum Communications Inc. (SPRD) gained after Bank of America Corp. said rising smartphone use will boost Asian semiconductor makers.
- [By Brian Pacampara]
What: Shares of Chinese smartphone chip maker Spreadtrum Communications (NASDAQ: SPRD ) surged 17% today after Tsinghua University, through its subsidiary Tsinghua Unigroup, offered to acquire it for $1.4 billion.
- [By FinanceGuru]
The Chinese market no doubt is huge, but Skyworks is expected to face competition from Spreadtrum Communications (SPRD), which supplies TD-SCDMA, the 3G standard used by China Mobile. Currently, Spreadtrum is a primary supplier to local Chinese firms and analysts suggest that it supplies to two of the biggest Chinese smartphone companies, Huawei and ZTE, which strengthens its position.
Top Gas Utility Stocks To Watch Right Now: InSite Vision Inc (INSV)
InSite Vision Incorporated (InSite), incorporated in 1986, is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company's current portfolio of products is based on the Company's DuraSite sustained drug delivery technology. Its DuraSite sustained drug delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a wide variety of drug candidates. The Company is focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology. It may also utilize its DuraSite technology platform for the formulation of new ocular product candidates using either non drugs or compounds developed by others for non-ophthalmic indications.
AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin developed as a spectrum ocular antibiotic and approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Azithromycin has a spectrum of antibiotic activity and is used to treat respiratory and other infections in its oral and parenteral forms.
Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye). Besivance is the fluoroquinolone specifically developed for ophthalmic use. AzaSite Plus (ISV-502) is a fixed combination of azithromycin and dexamethasone in DuraSite for the treatment of ocular inflammation and infection (blepharitis and/or blepharoconjunctivitis).
DexaSite (ISV-305) is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. DexaSite is included in the Phase 3 clinical trial SPA for ! AzaSite Plus. The Company developed a topical formulation of the corticosteroid dexamethasone to treat eye inflammation caused by infections, injury, surgery or other conditions.
BromSite (ISV-303) is a DuraSite formulation of bromfenac in development for the treatment of post-operative inflammation and eye pain. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease.
The Company competes with Alcon Laboratories, Inc., Allergan, Inc., Bausch & Lomb, Novartis Ophthalmics, Johnson & Johnson, Merck & Co. and Pfizer.
Advisors' Opinion:- [By CRWE]
Today, INSV surged (+7.53%) up +0.014 at $.200 with 96,500 shares in play thus far (ref. google finance Delayed: 1:12PM EDT August 15, 2013).
InSite Vision Incorporated previously reported financial results for the quarter ended June 30, 2013. Revenues for the second quarter of 2013 were $19.2 million compared to $1.8 million for the same period in 2012. Included in the second quarter of 2013 were revenues of $15 million for the sale of the Besivance庐 royalty rights. Net income for the second quarter of 2013 was $12.1 million, or $0.09 per share, compared to a net loss of $6.8 million, or $0.05 per share, in the second quarter of 2012.
- [By CRWE]
Today, INSV surged (+2.77%) up +0.009 at $.334 with 24,100 shares in play thus far (ref. google finance Delayed: 11:27AM EDT July 8, 2013).
InSite Vision Incorporated previously reported it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its DuraSite庐 2 next-generation enhanced drug delivery system. DuraSite 2 provides a broad platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. The patent is expected to provide protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2.
- [By CRWE]
Today, INSV has shed (-2.74%) down -0.009 at $.320 with 15,483 shares in play thus far (ref. google finance Delayed: 10:59AM EDT June 28, 2013), but don�� let this get you down.
InSite Vision Incorporated previously reported the company has regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra�� from Inspire Pharmaceuticals Inc., a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada. AzaSite Xtra, formulated in InSite�� DuraSite庐 topical drug delivery system, is a product candidate intended for the topical treatment of ocular infections.
Top Gas Utility Stocks To Watch Right Now: Taiwan Semiconductor Manufacturing Co Ltd (TSM)
Taiwan Semiconductor Manufacturing Co., Ltd. is a Taiwan-based company principally engaged in the research, development, manufacture and distribution of integrated circuit (IC) related products. The Company operates its businesses through wafer manufacture, mask production, wafer testing and packaging components. The Company also involves in the provision of production management, customer services and design services. Its products and services are applied in the manufacture of personal computers and peripheral products, information related products, wire and wireless communication systems, automobile and industrial equipment, as well as consumer electronic products, such as digital disk players, digital televisions (TVs), game consoles, digital cameras, among others. Its customers include Altera, AMD, Broadcom, Marvell, NVIDIA, Qualcomm, Analog Devices, Freescale, NXP and Texas Instruments, among others. In July 2010, Taiwan Semiconductor Manufacturing Co. acquired mechanical and engineering equipment from ASML HONG KONG LTD. In September 2010, the Company acquired a set of equipments from ASML HONG KONG LTD. In December 2010, the Company acquired a set of equipment from TOKYO ELECTRON LTD., KLA-TENCOR CORP. and NOVELLUS SYSTEMS INTERNATIONAL,B.V. In January 2011, the Company announced that it had acquired a set of equipment from KLA-TENCOR CORP., a set of equipment and facility, and another set of equipment from VARIAN SEMI. EQUIP. ASSOCIATES GmbH. In March 2011, the Company acquired a set of equipments from Rudolph Technologies, Inc.In March 2011, the Company acquired a set of equipments from Rudolph Technologies, Inc. In May 2011, it acquired a set of equipments form APPLIED MATERIALS SOUTH EAST ASIA PACIFIC LTD., Hamatech APE Gmbh and CO. KG, TOKYO ELECTRON LTD., DAINIPPON SCREEN MFG. CO., LTD., and VARIAN SEMI. EQUIP. ASSOCIATES GMBH.
TSMC's customers include semiconductor companies, ranging from fabless semiconductor and systems companies, such as Advanced Micro Devices, In! c., Altera Corporation, Broadcom Corporation, Marvell Semiconductor Inc., MediaTek Inc., nVidia Corporation and Qualcomm Incorporated, to integrated device manufacturers, such as LSI Corporation, STMicroelectronics and Texas Instruments Inc. Fabless semiconductor and system companies accounted for approximately 80%, and integrated device manufacturers accounted for approximately 20% of its net sales as of December 31, 2009.
The Company manufactures semiconductors using CMOS and BiCMOS processes. The BiCMOS process combines the speed of the bipolar circuitry and the power consumption and density of the CMOS circuitry. It uses the CMOS process to manufacture logic semiconductors, memory semiconductors, including static random access memory (SRAM), flash memory, mixed-signal/ radio frequency (RF) semiconductors, which combine analog and digital circuitry in a single semiconductor, micro-electro-mechanical-system (MEMS), which combines micrometer featured mechanical parts, analog and digital circuitry in a single semiconductor, and embedded memory semiconductors, which combine logic and memory in a single semiconductor. The BiCMOS process is used to make high-end mixed-signal and other types of semiconductors.
Advisors' Opinion:- [By Dividend]
Taiwan Semiconductor Manufacturing (TSM) has a market capitalization of $85.85 billion. The company employs 39,267 people, generates revenue of $16.931 billion and has a net income of $5.550 billion. Taiwan Semiconductor Manufacturing�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $10.448 billion. The EBITDA margin is 61.71 percent (the operating margin is 34.84 percent and the net profit margin 32.78 percent).
- [By Stephen Simpson, CFA]
While Mattson has a longer history in this market, the battle between Mattson and Ultratech (and flash annealing versus LSA) will be an interesting one to watch. The engineering papers I have read seem to give the edge to LSA for its better minimization of pattern effects (differences in energy absorption that cause nonuniformities in the chip), but Mattson argues that its new Millios tool delivers real advantages at 20nm and below in terms of process temperature flexibility, speed, and performance. To that end, both Samsung and TSMC (TSM) have been evaluating these tools in pilot production lines.
- [By Ashraf Eassa]
Is the tide turning?
According to Digitimes, chip manufacturer Taiwan Semiconductor (NYSE: TSM ) , or TSMC, has apparently begun to see an uptick in orders from PC-levered names such as AMD (NYSE: AMD ) and NVIDIA. (Intel builds its chips at its own manufacturing plants). While this is mildly positive for TSMC, which is also levered to the fast-growing mobile markets, it could end up being very positive for Intel and the PC-levered names in general.
No comments:
Post a Comment